Deverra Therapeutics
SEATTLE, WA · Founded 2019 · CIK 0001822782 · Biotech · Private
Universal donor cell therapies for cancer and other diseases
devetrx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $2.5M
- 2 Form D · Sep 2023
- 37 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 1 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $75,000 | |
| Private capital raised | Form D · SEC | $2,388,889 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2532 | STEMLINE THERAPEUTICS INC | — | $2.6M |
| 2533 | Form Bio | — | $16M |
| 2534 | A2 THERAPEUTICS, INC. | — | — |
| 2535 | Deverra Therapeutics | — | $2.5M |
| 2536 | ELIAS Animal Health, LLC | — | $2.4M |
| 2537 | BIOIO, LLC | — | — |
| 2538 | EIKONIZO THERAPEUTICS, INC. | — | $2.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Colleen DelaneyExecutive Officer
- Michael YurkowskyDirector · Executive Officer
Patents
- Nk Cell Compositions And Preparations For Immunotherapy And Methods For Their Productiongranted
- Compositions And Methods For Culturing Hematopoietic Stem And Progenitor Cellsapplication
- Compositions And Methods For Improving Treatment Outcomes For Patients Having Hematological Malignancies Using An Expanded Stem Cell Productapplication
- Nk Cell Composition And Preparations For Immunotherapy And Methods For Their Productionapplication
- Compositions And Methods For Improving Treatment Outcomes For Patients Having Hematological Malignancies Using An Expanded Stem Cell Productapplication
- NK Cell Preparations for Immunotherapyapplication
- Compositions And Methods For Culturing Hematopoietic Stem And Progenitor Cellsapplication
- NK Cell Preparations for Immunotherapyapplication
- Methods For The Generation Of A Monocyte/macrophage Cell Product From Expanded Cord Blood CD34+ Hematopoietic Stem And Progenitor Cellsapplication
- Methods For The Generation Of A Monocyte/macrophage Cell Product From Expanded Cord Blood CD34+ Hematopoietic Stem And Progenitor Cellsapplication
- Methods For The Generation Of A Monocyte/macrophage Cell Product From Expanded Cord Blood CD34+ Hematopoietic Stem And Progenitor Cellsapplication
- Compositions And Methods For Culturing Hematopoietic Stem And Progenitor Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.